[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"post-operative-atrial-fibrillation-poaf\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:post-operative-atrial-fibrillation-poaf":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100515453","phase-1-anthocyanin-rich-table-grape-powder-for-prophylaxis-of-post-operative-atrial-fibrillation-100515453",false,"NCT05991700","Anthocyanin-Rich Table Grape Powder for Prophylaxis of Post-Operative Atrial Fibrillation","Inclusion Criteria:\n\n* Males and female patients (age 50-79) at the Mitral Valve Clinic\u002FCVC undergoing elective cardiac surgery for mitral valve repair without the Cox MAZE procedure (MVR patients also undergoing CABG and\u002For tricuspid valve repair are also eligible)\n* In sinus rhythm (no pre-operative atrial fibrillation)\n\nExclusion Criteria:\n\n* Age ≥ 80 years\n* Diagnosed pre-operative chronic or paroxysmal AF\n* Prior ablation procedure for AF\n* Previous cardiac surgery\n* Implanted pacemaker\n* Active smoker\n* Comorbidities such as congenital or cardiac re-operation\n* Use of antiarrhythmic agents\n* Active inflammatory or infectious disease or malignancy\n* Diagnosed autoimmune disease\n* Corticosteroid or other immunomodulatory or immunosuppressive medication\n* Risk factors for POAF including low ejection fraction (EF) (EF\\\u003C50%), left atrial (LA) dilation (LA\\>5.0 cm), and high degree of mitral regurgitation (grade 3-4).","ALL","18 Years","79 Years",{"count":19,"type":20},70,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","Postoperative atrial fibrillation (POAF) is a common complication following cardiac surgery and leads to worse outcomes. POAF is thought to be caused by the inflammatory state following cardiac surgery. It may be that anti-inflammatory medications could lower the occurrence of POAF, however many typical anti-inflammatory medications, such as ibuprofen, are contraindicated in the post cardiac surgery patient due to increased risks of bleeding. If a drug was identified with anti-inflammatory properties with minimal deleterious side effects, this could be broadly applied to cardiac surgery patients for the prevention of POAF. Interestingly, several small trials have shown that medications that alter transcription of inflammatory markers lead to decreased POAF. Furthermore, we have shown that phytochemicals, such as those found in grapes, have excellent bioavailability and can affect cardiac gene transcription related to inflammation. In this study, we propose to evaluate the efficacy of preoperative administration of concentrated grape powder in the prevention of POAF.",[27],"Post-operative Atrial Fibrillation (POAF)","RECRUITING","2026-04-24",{"date":31,"type":32},"2026-04-27","ACTUAL",{"date":34,"type":32},"2026-03-23",{"date":36,"type":20},"2027-08",{"name":38,"class":39},"University of Michigan","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":65},"100424273","the-defipace-study-100424273","NCT04804748","The DefiPace Study","Safety and Efficacy of Low-energy Electrical Cardioversion With or Without Bi-atrial Pacing in Patients With Post-operative Atrial Fibrillation in a Real World Setting - The DefiPace Study","Defipace","Inclusion Criteria:\n\n* Patient is scheduled to undergo elective open chest cardiac surgery (bypass and \u002F or valve surgery)\n* Patient is at least 18 years old\n* Patient with isolated bypass surgery is at least 70 years old\n* Patient with valve surgery is at least 60 years old\n* Patient provides written informed consent prior to the procedure\n* Phase B only: patient is scheduled for TMA implantation during the elective cardiac surgery and is potentially eligible for DefiPace use\n\nExclusion Criteria:\n\n* Clinical history of either permanent, persistend or paroxysmal atrial fibrillation\n* Permanent pacemaker\u002Fdefibrillator, other intra-cardiac active implanted electronic devices\n* Minimally-invasive surgery\n* Recent stroke within the last 3 months\n* A history of or current endocarditis\n* Pregnacy at the time of surgery",{"count":50,"type":20},450,"OBSERVATIONAL","Prospective, non-interventional, multi-center, international registry in two phases in consecutive patients undergoing elective cardiac surgery.\n\nThe DefiPace registry is designed in two phases\n\n1. to document the standard of care in 50 patients with atrial fibrillation (AF)\n2. to assess the treatment and outcomes of patients with post-operative atrial fibrilllation using low-energy cardioversion and subsequent bi-atrial pacing in clinical practice in 100 patients",[54],"Post-operative Atrial Fibrillation POAF","2026-03-25",{"date":57,"type":32},"2026-03-30",{"date":59,"type":32},"2023-03-28",{"date":61,"type":20},"2026-08-31",{"name":63,"class":64},"Institut für Pharmakologie und Präventive Medizin","NETWORK",10]